GP Dr Rob Hungerford presents a woman with obesity who has achieved significant weight loss, but remains above treatment goals, exploring dose escalation and STEP UP trial outcomes.
In this Quick Case:
GP Dr Rob Hungerford presents a woman with obesity who has achieved significant weight loss on Wegovy® but remains above her treatment goals. The case explores the STEP UP trial data and the potential benefits of dose escalation to support further weight loss and personalised obesity management (6 mins).
This video was produced with funding from Novo Nordisk.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events to the TGA here.
PBS Information: This product is not listed on the PBS.
Please review the full Product information before prescribing. The full Product Information for Wegovy® (semaglutide) can be accessed here.
Novo Nordisk Pharmaceuticals Pty Ltd. ABN 40 002 879 996. Level 10, 118 Mount Street, North Sydney NSW 2060. Novo Nordisk Medical Information (Australia) 1800 668 626. www.novonordisk.com.au. ® Registered trademark of Novo Nordisk A/S. AU26SEMO00396. September 2026.
